BPL-003 Efficacy and Safety in Treatment Resistant Depression
This study explores how safe and effective BPL-003 is for people with Treatment Resistant Depression (TRD). TRD is when depression doesn't improve after trying at least two different medications. In this study, 225 participants will be given a single dose of BPL-003 through the nose. They will receive help from psychologists before, during, and after the treatment. The study will last for about 8 weeks with follow-up checks.
To join, you need to have moderate depression and may need to stop any current antidepressants. People with certain mental health conditions, substance abuse issues, or specific medical problems can't participate. Also, if you have a history of seizures or certain heart conditions, you might not be eligible.
- The study lasts 8 weeks with follow-up visits.
- Participants receive psychological support throughout.
- Some people may need to stop current medications.
Note: Participants will be selected based on specific health criteria, and precautions are in place to ensure safety during the study. 😊
Study details
NCT05870540
Beckley Psytech Limited
8 July 2024
Not finding the right Trial?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
FAQs
Learn more about clinical trials
What is a clinical trial?
Why should I take part in a clinical trial?
How long does a clinical trial take place?
Do I get compensated for taking part in clinical trials?
How safe are clinical trials?
Study Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.